Evidence map›Paper›PMID 39600613›Full record

ArticleClinical ophthalmology (Auckland, N.Z.)2024

"Outcomes of Iontophoresis Cross-Linking in Asymmetric Keratoconus: A Retrospective Analysis of High Visual Acuity Eyes Under 25 Years Old".

Vanessa Ferraro, Francesco Santoru, Gianmaria Barone, Pietro Rosetta

Abstract read
In one paragraph

Article in Clinical ophthalmology (Auckland, N.Z.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Transepithelial corneal cross-linking: a review.International ophthalmology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Vanessa FerraroDepartment of Ophthalmology, IRCCS Humanitas Research Hospital, Milan, Italy.ORCID 0000-0002-5018-1853
Francesco SantoruDepartment of Ophthalmology, IRCCS Humanitas Research Hospital, Milan, Italy.ORCID 0000-0002-7463-2479
Gianmaria BaroneDepartment of Ophthalmology, IRCCS Humanitas Research Hospital, Milan, Italy.
Pietro RosettaDepartment of Ophthalmology, Humanitas San Pio X, Milano, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To assess the long-term outcomes of transepithelial iontophoresis cross-linking (I-CXL) for early keratoconus with high visual acuity under the age of 25. Methods: This retrospective study was conducted at the Department of Ophthalmology, Humanitas San Pio X, Milan, Italy, on data collected between 2015 and 2020. Patients diagnosed with early keratoconus and under the age of 25 who underwent to I-CXL were retrospectively reviewed and included in the study if they fulfilled the following criteria: high visual acuity (LogMAR ≤ 0.2) before I-CXL and the fact that the fellow, most advanced eye, had been treated with epithelium off CXL (S-CXL). Corrected distance visual acuity (CDVA), spherical equivalent refraction, thinnest corneal thickness, corneal topography and tomography were assessed at baseline and at least 24 months of follow-up, using Pentacam. Statistical analysis was performed with STATA SE version 17. Results: Twenty patients with a mean age of 18.5 ± 3.75 months were included. The median follow-up time was 24 months. The statistical analysis showed no significant change over time in CDVA, maximum keratometry and A, B, C values of the Belin Progression Display. Mean baseline CDVA was 0.03 ± 0.07 logMAR, whereas at 24-month was 0.01 ± 0.04. Mean spherical equivalent was -1.29 ± 1.38D at baseline and -1.05 ± 1.51D after 24 months. Preoperative maximum keratometry was 48.35 ± 4.95 D and 48.56 ± 4.96 D after the 2 years of follow-up. Mean baseline A value was 7.13 ± 1.66 mm and 24-month postoperative was 7.43 ± 0.48 mm. Average B value was 5.87 ± 0.55 mm prior to surgery, while it was 5.83 ± 0.60 mm after the last follow-up. Mean baseline and 24-month thinnest point were 498.9 ± 34.29 µm and 500.10 ± 33.45 µm respectively. None of the patients showed a progression of keratoconus. Conclusion: I-CXL may be considered as a beneficial treatment option for young patients with less advanced keratoconus, although further consensus on patient selection criteria is needed.

Indexed as

cross-linking treatmentectasia progressioniontophoresiskeratoconus

Identifiers

PMID39600613
PMCPMC11590656

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.